#Novartis is an active hashtag on Bluesky. In the last 30 days, 13 people shared 25 posts with it — around 1 a day. Activity is up 100% versus the previous week, peaking on Sep 29 with 5 posts.
statnews.com
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
statnews.com
Pharmalittle: We're reading about Roche investments in Germany, a Gilead bowel disease drug, and more
Roche is reviewing all future investments in Germany over health care cost-cutting policies, with a top executive citing a loss of trust
statnews.com
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
pharmaphorum.com
Rhapsido is first drug cleared for chronic hives disorder SD
Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.
www.narrowit.com
Novartis Licenses Abogen RNA Drug for $575 Million Upfront | Narrowit.com
Abogen granted Novartis worldwide rights to ABO2203 and options on other RNA programs in a deal carrying $575 million upfront and contingent milestones.
statnews.com
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
statnews.com
Pharmalittle: We're reading about Roche investments in Germany, a Gilead bowel disease drug, and more
Roche is reviewing all future investments in Germany over health care cost-cutting policies, with a top executive citing a loss of trust
statnews.com
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
pharmaphorum.com
Rhapsido is first drug cleared for chronic hives disorder SD
Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.
www.narrowit.com
Novartis Licenses Abogen RNA Drug for $575 Million Upfront | Narrowit.com
Abogen granted Novartis worldwide rights to ABO2203 and options on other RNA programs in a deal carrying $575 million upfront and contingent milestones.
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.
